HLG NOMICS is opening its retail investor subscription for its KOSDAQ listing. As a company specializing in active pharmaceutical ingredients (APIs), it plans to further strengthen its production capacity and R&D competitiveness through this initial public offering (IPO).

According to the financial investment industry, HLG NOMICS' retail subscription will take place over two days from July 13 to 14. The indicative price band ranges from 18,500 to 21,500 won, with KB Securities serving as the lead underwriter. Institutional demand forecasting is currently underway, and the final offering price and institutional subscription rate will be determined based on its results.

HLG NOMICS primarily manufactures APIs, which are core ingredients used in the production of finished pharmaceutical products and are critical factors that determine the quality and stability of drugs. The company's products are APIs for prescription drugs, applied to medications used under a doctor's prescription and supervision. Due to their pharmacological actions and formulation characteristics, prescription drugs require medical diagnosis and prescription, and using them without proper medical supervision can cause side effects or medical risks, distinguishing them from over-the-counter drugs. Therefore, it is essential for API suppliers for prescription drugs to have a production system that meets strict manufacturing quality control and regulatory standards.

The API industry is showing steady growth, driven by an aging population, the rise in chronic diseases, and the expansion of the biopharmaceutical market. In particular, as global pharmaceutical companies strengthen supply chain stability, stable production capacity and quality competitiveness of APIs are emerging as key elements of corporate value. The market is closely watching whether the funds raised through this offering will be deployed toward production facility expansion, R&D investment, and business competitiveness enhancement.

However, investment performance in IPO stocks may vary depending on market conditions, corporate performance, and supply and demand dynamics after listing, so investors need to make careful decisions after thoroughly reviewing the securities registration statement and investment prospectus.

[This article was written with the assistance of AI. AI was utilized in the writing process, and the final content was reviewed based on factual accuracy. This article is not a solicitation to invest in any specific IPO, and responsibility for investment decisions lies solely with the investor.]